In one paragraphArticle in Cardiovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Sandeep ManandharWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Drive NE, Atlanta, GA 30322, USA.ORCID 0000-0002-7323-0339 Tilak PathakWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Drive NE, Atlanta, GA 30322, USA.
Kenneth B MarguliesCardiovascular Institute, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-8093-4465 Anant MadabhushiWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 1760 Haygood Drive NE, Atlanta, GA 30322, USA.ORCID 0000-0002-5741-0399 Eliot G PeysterCardiovascular Institute, University of Pennsylvania, Philadelphia, PA 19104, USA.
Funding
RADx Innovation Funnel for HIV diagnostics – Validation Center75N92022D00015 · NIBIB · EMORY UNIVERSITY · PI PARSLOW, TRISTRAM G. · 2022 to 2025
$19.9MProstate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas SouthwesternU01CA113913 · NCI · EMORY UNIVERSITY · PI Martin G. Sanda · 2005 to 2026
$16.4MP-CARRS-BRAIN: Multi-domain (genetic, socio-behavioral, vascular) risk factors and prediction of Alzheimer’s Disease continuum in South Asians in IndiaR01AG089759 · NIA · EMORY UNIVERSITY · PI Suvarna Alladi, ALLAN I LEVEY · 2024 to 2026
$12.8MKPMP Kidney Mapping and Atlas Project (KMAP)U01DK133090 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jonathan Himmelfarb, Matthias Kretzler · 2022 to 2026
$10.4MSpatial Transcriptomics Explorer (STE): An open-source resource for visualizing spatial gene expression dataU24CA274494 · NCI · SAGE BIONETWORKS · PI Jineta Banerjee, Susheel Varma · 2022 to 2026
$10.1MProject 3: Dynamics of Immune Signatures and Microbiome in Patients with Cervical Pre-Cancer and Cancer Among Women.U54CA302465 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Erin Nicole Kobetz · 2025 to 2026
$6.9MComputational Pathology of Proteinuric DiseasesR01DK118431 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI BARISONI, LAURA MARIACHIARA, HODGIN, JEFFREY BENTON · 2018 to 2025
$3.6MComputer-Assisted Histologic Evaluation of Cardiac Allograft RejectionR01HL151277 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MADABHUSHI, ANANT, MARGULIES, KENNETH BER · 2020 to 2023
$3.2MOral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)R01CA249992 · NCI · EMORY UNIVERSITY · PI LEWIS, JAMES, MADABHUSHI, ANANT · 2021 to 2025
$3.2MProstate cancer risk stratification via computational 3D pathologyR01CA268207 · NCI · UNIVERSITY OF WASHINGTON · PI Jonathan T.C. Liu, Anant Madabhushi · 2022 to 2026
$3.1MPrognostic and Predictive Digital Tissue Image Assay for Prostate CancerR01CA268287 · NCI · EMORY UNIVERSITY · PI GUPTA, SHILPA, LAL, PRITI · 2022 to 2025
$3.0MRADIOMIC APPROACHES TO IMPROVE TARGETING FOR ATRIAL FIBRILLATION CATHETER ABLATIONR01HL158071 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI BARNARD, JOHN, CHUNG, MINA KAY · 2021 to 2024
$2.9MAdvanced Research Projects Agency for Health (ARPA-H) D25CA00140-00BLRD VA I01 BX004121BLRD VA IK6 BX006185Bogle Family FundBreast Cancer Research FoundationBristol Myers SquibbCSRD VA I01 CX002622CSRD VA I01 CX002776Innovation in Cancer InformaticsInstitute for Technology in HealthcareKidney Mapping and Atlas Project (KMAP) U01DK133090-01National Institute of Allergy and Infectious Diseases R01AI175555-01A1National Institute of Allergy and Infectious Diseases R01HL151277-01A1NCI NIH HHS R01 CA249992NCI NIH HHS R01CA249992-01A1NCI NIH HHS R01 CA257612NCI NIH HHS R01CA257612-01A1NCI NIH HHS R01 CA264017NCI NIH HHS R01CA264017-01NCI NIH HHS R01 CA268207NCI NIH HHS R01CA268207-01NCI NIH HHS R01 CA268287NCI NIH HHS R01CA268287-01A1NCI NIH HHS R01HL158071NCI NIH HHS R01HL170152NCI NIH HHS U01 CA113913NCI NIH HHS U01CA113913-16A1NCI NIH HHS U01 CA269181NCI NIH HHS U01CA269181-01NCI NIH HHS U24 CA274494NCI NIH HHS U24CA274494-01NCI NIH HHS U54 CA302465NCI NIH HHS U54CA302465-01NHLBI NIH HHS R01 HL151277NHLBI NIH HHS R01 HL158071NHLBI NIH HHS R01HL158071-01A1NHLBI NIH HHS R01 HL170152NIAID NIH HHS R01 AI175555NIA NIH HHS R01 AG089759NIA NIH HHS R01AG089759NIBIB NIH HHS 75N92022D00015NIDDK NIH HHS R01 DK118431NIDDK NIH HHS R01DK118431NIDDK NIH HHS U01 DK133090NIH HHS 1OT2OD038065-01NIH HHS 75N92022D00015NIH HHS OT2 OD038065NLM NIH HHS R01 LM013864NLM NIH HHS R01LM013864-01A1Prevent Cancer FoundationScott Mackenzie FoundationUnited States Department of Veterans Affairs IBX004121VA Biomedical Laboratory Research and Development Service I01CX002622VA Biomedical Laboratory Research and Development Service I01CX002776VA Biomedical Laboratory Research and Development Service IK6BX006185VA Research and Development Office through the Lung Precision Oncology Programmes LPOP-L0021W.W. Smith Charitable Trust
6 · The paper itselfAbstract
aimsCardiac remodelling drives heart failure (HF), yet microstructural drivers in human tissue remain poorly defined due to the limited resolution of clinical imaging. This study sought to quantitatively assess cardiomyocyte morphometry and its relationship with clinical phenotypes. METHODS AND
resultsWe developed MyoSAM, a deep learning framework for quantitative morphometric characterization of H&E-stained whole-slide images (N = 334 patients). Cardiomyocyte size was quantified using the myocyte maximum inscribed circle (MMIC) radius, along with measures of nuclear size and perinuclear-halo size, interstitial and macrodomain stromal fractions. Independent associations between these histological features and clinical variables were assessed using multivariable regression and patient-level linear mixed-effects models to account for clustering of cellular measurements within individuals. MMIC radius was the strongest histological predictor of left ventricular mass index (LVMI; P < 0.001) and was positively correlated with clinical HF (Pearson's r = 0.77, P < 0.001). In severe coronary artery disease, the association between LVMI and MMIC radius was significantly attenuated (P = 0.001), indicating that myocyte hypertrophy was diminished despite increased mass; instead, remodelling shifted towards greater interstitial stromal expansion (P = 0.025). Males exhibited larger MMIC radii than females (fold-changes 1.08, P = 0.003). Distinct aetiology-specific signatures emerged: anthracycline-treated hearts showed large MMIC radii and perinuclear halos with minimal stroma, while non-ischaemic cardiomyopathy exhibited the greatest nuclear enlargement and stromal macrodomain expansion.
conclusionComputational pathology enables high-resolution characterization of myocardial remodelling, revealing distinct microstructural phenotypes across sex, coronary disease burden, and HF aetiology that may improve cardiac phenotyping and risk stratification.
Indexed as
Coronary Artery DiseaseHeart FailureHypertrophy, Left VentricularMyocytes, CardiacVentricular RemodelingAgedCell SizeFemaleHumansImage Interpretation, Computer-AssistedMaleMiddle AgedPhenotypeSex FactorsCardiomyocyteCardiovascular diseaseHeart failure
Identifiers
PMID42530239
PMCPMC13653500
What OpenQuestion holds
Textmetadata
Read underepoch 390